{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:28:28Z","timestamp":1792024108434,"version":"4.4.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2021\/WAB13\/UCSI\/02\/1"],"award-info":[{"award-number":["FRGS\/1\/2021\/WAB13\/UCSI\/02\/1"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interferons (IFNs) are important in controlling the innate immune response to viral infections. Besides that, studies have found that IFNs also have antimicrobial, antiproliferative\/antitumor and immunomodulatory effects. IFNs are divided into Type I, II and III. Type I IFNs, in particular IFN-\u03b1, is an approved treatment for hepatitis C. However, patients developed neuropsychological disorders during treatment. IFN-\u03b1 induces proinflammatory cytokines, indoleamine 2,3-dioxygenase (IDO), oxidative and nitrative stress that intensifies the body\u2019s inflammatory response in the treatment of chronic inflammatory disease. The severity of the immune response is related to behavioral changes in both animal models and humans. Reactive oxygen species (ROS) is important for synaptic plasticity and long-term potentiation (LTP) in the hippocampus. However, excess ROS will generate highly reactive free radicals which may lead to neuronal damage and neurodegeneration. The limbic system regulates memory and emotional response, damage of neurons in this region is correlated with mood disorders. Due to the drawbacks of the treatment, often patients will not complete the treatment sessions, and this affects their recovery process. However, with proper management, this could be avoided. This review briefly describes the different types of IFNs and its pharmacological and clinical usages and a focus on IFN-\u03b1 and its implications on depression.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1048592","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T05:28:15Z","timestamp":1677043695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Interferon therapy and its association with depressive disorders \u2013 A review"],"prefix":"10.3389","volume":"14","author":[{"given":"Jing Yung","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Xiang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey Siew Foong","family":"Kow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengfan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau Ling","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Tatt","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_166","article-title":"Role of inflammation in depression and treatment implications","volume":"250","author":"Felger","year":"2019","journal-title":"Handb Exp Pharmacology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004411","article-title":"\u2018Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis\u2019","volume":"89","author":"Rossi","year":"2017","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.11.007","article-title":"Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala","volume":"91","author":"Zheng","year":"2021","journal-title":"Brain Behavior Immun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1177\/1359105316658967","article-title":"Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions","volume":"23","author":"Hepgul","year":"2018","journal-title":"J Health Psychol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ijnp\/pyx083","article-title":"\u2018Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms\u2019","volume":"21","author":"Borsini","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(03)00173-2","article-title":"\u2018Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment\u2019","volume":"54","author":"Capuron","year":"2003","journal-title":"Biol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000126396","article-title":"\u2018Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro\u2019","volume":"57","author":"Gisslinger","year":"1993","journal-title":"Neuroendocrinology"},{"key":"B8","article-title":"\u2018Depression and suicide ideation in chronic hepatitis c patients untreated and treated with interferon: prevalence, prevention, and treatment\u2019","volume":"28","author":"Lucaciu","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00592-0","article-title":"Type I and III interferon responses in SARS-CoV-2 infection","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"\u2018Interferon induction and function at the mucosal surface\u2019","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"\u2018Complex modulation of cell type-specific signaling in response to type I interferons\u2019","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290309","article-title":"The host type I interferon response to viral and bacterial infections","volume":"15","author":"Perry","year":"2005","journal-title":"Cell Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2012.09.003","article-title":"\u2018Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise\u2019","volume":"33","author":"Felger","year":"2012","journal-title":"Front Neuroendocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939233","article-title":"\u2018Type I IFN regulate DC turnover in vivo\u2019","volume":"39","author":"Mattei","year":"2009","journal-title":"Eur J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8296-5","article-title":"\u2018Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity\u2019","volume":"44","author":"Axtell","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12010","article-title":"\u2018IFN-\u03b1 subtypes: Distinct biological activities in anti-viral therapy\u2019","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/j.1365-2036.2004.02170.x","article-title":"Review article: Pegylated interferons: Chemical and clinical differences","volume":"20","author":"Foster","year":"2004","journal-title":"Alimentary Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.v30.i2.30","article-title":"\u2018Treatment of hepatitis c virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling\u2019","volume":"30","author":"Rong","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205179","article-title":"\u2018Mechanisms of interferon-alpha induced apoptosis in malignant cells\u2019","volume":"21","author":"Thyrell","year":"2002","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903510963","article-title":"Interferon-alpha as angiogenesis inhibitor: Learning from tumor models","volume":"43","author":"Indraccolo","year":"2010","journal-title":"Autoimmunity"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.11.1188","article-title":"\u2018Resolving familial Mediterranean fever attacks with interferon alpha\u2019","volume":"35","author":"Tankurt","year":"1996","journal-title":"Br J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.9.1005","article-title":"\u2018The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study\u2019","volume":"36","author":"Tunca","year":"1997","journal-title":"Br J Rheumatol"},{"key":"B23","article-title":"\u2018The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial\u2019","volume":"22","author":"Tunca","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"B24","article-title":"Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever","volume":"35","author":"Tweezer-Zaks","year":"2008","journal-title":"J Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000277703.74115.d2","article-title":"\u2018Interferon-beta\u2019","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03055.x","article-title":"Clinical uses of interferons","volume":"65","author":"Friedman","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2016.06.001","article-title":"\u2018Interferon beta: From molecular level to therapeutic effects\u2019","volume":"326","author":"Haji Abdolvahab","year":"2016","journal-title":"Int Rev Cell Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902542","article-title":"\u2018IFN-\u03b2 inhibits dendritic cell migration through STAT-1\u2013mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9\u2019","volume":"184","author":"Yen","year":"2010","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237994.95410.ce","article-title":"\u2018Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS\u2019","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097899","article-title":"\u2018Interferon beta for rheumatoid arthritis: New clothes for an old kid on the block\u2019","volume":"68","author":"Vervoordeldonk","year":"2009","journal-title":"Ann Rheumatic Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","article-title":"\u2018Targeting the tumor microenvironment with interferon-\u03b2 bridges innate and adaptive immune responses\u2019","volume":"25","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004364","article-title":"\u2018A rapid screening assay identifies monotherapy with interferon-\u00df and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus\u2019","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis921","article-title":"\u2018Interferon-\u03b2 therapy prolongs survival in rhesus macaque models of Ebola and marburg hemorrhagic fever\u2019","volume":"208","author":"Smith","year":"2013","journal-title":"J Infect Dis"},{"key":"B34","unstructured":"Efficacy and safety of PEG-interferon alpha-2a plus ribavirin in genotype 1 chronic hepatitis c participants co-infected with human immunodeficiency virus"},{"key":"B35","unstructured":"Pegylated interferon alfa-2a plus low dose ribavirin for treatment-na\u00efve hemodialysis patients with chronic hepatitis c"},{"key":"B36","unstructured":"A study of pegylated interferon alfa-2a and lamivudine in patients with hbeag-negative chronic hepatitis b virus (HBV)"},{"key":"B37","unstructured":"A study of pegylated interferon alfa-2a in combination with lamivudine or entecavir compared with untreated control group in children with hepatitis b envelope antigen (hbeag)-positive chronic hepatitis b (CHB) in the immune-tolerant phase"},{"key":"B38","unstructured":"Antiviral activity of PEG-IFN-alpha-2A in chronic HIV-1 infection"},{"key":"B39","unstructured":"Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer"},{"key":"B40","unstructured":"Temozolomide alone or with pegylated interferon-alpha 2b (PGI) in melanoma patients"},{"key":"B41","unstructured":"Efficacy and safety study of peginterferon beta-1a in participants with relapsing multiple sclerosis - full text view. efficacy and safety study of peginterferon beta-1a in participants with relapsing multiple sclerosis"},{"key":"B42","unstructured":"Long-term safety and efficacy study of peginterferon beta-1a - full text view. long-term safety and efficacy study of peginterferon beta-1a"},{"key":"B43","unstructured":"A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis - full text view. a study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis"},{"key":"B44","unstructured":"A phase 2 study of interferon beta-1a (Avonex\u00ae) in ulcerative colitis"},{"key":"B45","unstructured":"Interferon-beta1a (AVONEX) treatment of ulcerative colitis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4236\/abb.2013.47A3002","article-title":"The talented interferon-gamma","volume":"4","author":"Lin","year":"2013","journal-title":"Adv Bioscience Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cytogfr.2009.02.004","article-title":"\u2018Interferon-gamma: A historical perspective\u2019","volume":"20","author":"Billiau","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00594-15","article-title":"\u2018Interferon gamma prolongs survival of varicella-zoster virus-infected human neurons in vitro\u2019","volume":"89","author":"Baird","year":"2015","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26782","article-title":"\u2018An effective interferon-gamma-mediated inhibition of hepatitis c virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis c in human immunodeficiency virus-positive patients\u2019","volume":"59","author":"Kokordelis","year":"2014","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s0300-9084(01)01251-2","article-title":"\u2018Interferon-gamma inducible exchanges of 20S proteasome active site subunits: Why?\u2019","volume":"83","author":"Groettrup","year":"2001","journal-title":"Biochimie"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/aja.1001700319","article-title":"\u2018Antigen processing and presentation by macrophages\u2019","volume":"170","author":"Allen","year":"1984","journal-title":"Am J Anat"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1996.516576.x","article-title":"\u2018Upregulation of MHC class II antigen on dendritic cells from hepatitis b virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen\u2019","volume":"87","author":"Akbar","year":"1996","journal-title":"Immunology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1998.0357","article-title":"\u2018Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 AND CD4\u2019","volume":"10","author":"Rongcun","year":"1998","journal-title":"Cytokine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086844","article-title":"\u2018Interferon-\u03b3 induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis\u2019","volume":"9","author":"Thelemann","year":"2014","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80085-0","article-title":"\u2018Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis\u2019","volume":"11","author":"Xaus","year":"1999","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243010-00008","article-title":"\u2018Interferon gamma-1b\u2019","volume":"43","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145865","article-title":"\u2018RNA-dependent protein kinase is required for interferon-\u03b3-induced autophagy in MG63 osteosarcoma cells\u2019","volume":"802","author":"Xu","year":"2021","journal-title":"Gene"},{"key":"B58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"\u2018Interferon-gamma (IFN-\u03b3): Exploring its implications in infectious diseases\u2019","volume":"9","author":"Kak","year":"2018","journal-title":"Biomolecular Concepts"},{"key":"B59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199001043220104","article-title":"\u2018Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma\u2019","volume":"322","author":"Badaro","year":"1990","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102213240801","article-title":"\u2018A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease\u2019","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"B61","unstructured":"Effects of interferon-gamma on cavitary pulmonary tuberculosis in the lungs"},{"key":"B62","unstructured":"Use of ACTIMMUNE in patients with ADO2"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"\u2018Shared and distinct functions of type I and type III interferons\u2019","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00985-20","article-title":"\u2018Type I and type III interferons restrict SARS-COV-2 infection of human airway epithelial cultures\u2019","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J Virol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: The biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-190520","article-title":"\u2018Comparative ability of IL-12 and IL-28B to regulate treg populations and enhance adaptive cellular immunity\u2019","volume":"113","author":"Morrow","year":"2009","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.4.2474","article-title":"\u2018An important role for type III interferon (IFN-lambda\/IL-28) in TLR-induced antiviral activity\u2019","volume":"180","author":"Ank","year":"2008","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2015-0021","article-title":"\u2018IFN-\u03bb cancer immunotherapy: new kid on the block\u2019","volume":"8","author":"Lasfar","year":"2016","journal-title":"Immunotherapy"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3653","article-title":"\u2018Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma\u2019","volume":"66","author":"Lasfar","year":"2006","journal-title":"Cancer Res"},{"key":"B70","unstructured":"A study to evaluate pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection (LIMT)"},{"key":"B71","unstructured":"Study of PEG-rIL-29 (or PEF-IFN lambda) in subjects with chronic hepatitis c virus infection"},{"key":"B72","unstructured":"Dose ranging study of pegylated interferon lambda in patients with Hepatitis B and positive for Hepatitis B e Antigen (LIRA-B) \u2013 full text view. Full Text View \u2013 ClinicalTrials.gov"},{"key":"B73","article-title":"How to increase serotonin in the human brain without drugs","volume":"32","author":"Young","year":"2007","journal-title":"J Psychiatry Neurosci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137022","article-title":"\u2018Quinolinic acid responses during interferon-\u03b1-induced depressive symptomatology in patients with chronic hepatitis c infection - a novel aspect for depression and inflammatory hypothesis\u2019","volume":"10","author":"Baranyi","year":"2015","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17559","DOI":"10.1038\/s41598-017-17979-7","article-title":"\u2018Inhibition of human kynurenine aminotransferase isozymes by estrogen and its derivatives\u2019","volume":"7","author":"Jayawickrama","year":"2017","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001600","article-title":"\u2018IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity\u2019","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol Psychiatry"},{"key":"B77","article-title":"\u2018The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation\u2019","volume":"28","author":"Maes","year":"2007","journal-title":"Neuro Endocrinol Lett"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.06.001","article-title":"\u2018Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis c\u2019","volume":"25","author":"Galv\u00e3o-de Almeida","year":"2011","journal-title":"Brain Behavior Immun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/jir.1986.6.697","article-title":"\u2018Interferon-gamma enhances biosynthesis of pterins in peripheral blood mononuclear cells by induction of GTP-cyclohydrolase I activity\u2019","volume":"6","author":"Schoedon","year":"1986","journal-title":"J Interferon Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(03)02776-8","article-title":"\u2018Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier\u2019","volume":"978","author":"Kitagami","year":"2003","journal-title":"Brain Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"\u2018Glutamate as a neurotransmitter in the healthy brain\u2019","volume":"121","author":"Zhou","year":"2014","journal-title":"J Neural Transm"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0197-0186(01)00133-4","article-title":"\u2018Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes\u2019","volume":"40","author":"Tavares","year":"2002","journal-title":"Neurochemistry Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.06.200","article-title":"Insights from interferon-\u03b1-related depression for the pathogenesis of depression associated with inflammation, brain, behavior, and immunity","volume":"42","author":"Hoyo-Becerra","year":"2014"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.274","article-title":"\u2018Recurrence of depressive disorders after interferon-induced depression\u2019","volume":"7","author":"Chiu","year":"2017","journal-title":"Trans Psychiatry"},{"key":"B85","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression","volume":"29","author":"Wichers","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00264-1","article-title":"Depression induced by treatment with interferon-alpha in patients affected by hepatitis c virus","volume":"72","author":"Bonaccorso","year":"2002","journal-title":"J Affect Disorders"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(90)90043-h","article-title":"\u2018Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats\u2019","volume":"37","author":"V\u00e9csei","year":"1990","journal-title":"Pharmacology Biochemistry Behav"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/026988119601000312","article-title":"Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice","volume":"10","author":"Lapin","year":"1996","journal-title":"J Psychopharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.05.004","article-title":"\u2018A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness\u2019","volume":"35","author":"Maes","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082951","article-title":"\u2018interferon-alpha-induced serotonin uptake in jurkat t cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter\u2019","volume":"22","author":"Tsao","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.50","article-title":"\u2018Transcriptomics in interferon-\u03b1-treated patients identifies inflammation-, neuroplasticity- and oxidative stress-related signatures as predictors and correlates of depression\u2019","volume":"41","author":"Hepgul","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2006.09.007","article-title":"\u2018Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol\u2019","volume":"62","author":"Wichers","year":"2007","journal-title":"J Psychosom Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biopsych.2008.08.010","article-title":"\u2018Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression\u2019","volume":"65","author":"Raison","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"\u2018Psychiatric complications of long-term interferon alfa therapy\u2019","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Internal Med"},{"key":"B95","article-title":"\u2018Depression during interferon therapy in chronic hepatitis c patients \u2013 a prospective study\u2019","volume":"99","author":"Otsubo","year":"1997","journal-title":"Seishin shinkeigaku zasshi = Psychiatria neurologia Japonica"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis c","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/s0163-8343(02)00239-6","article-title":"\u2018Incidence and clinical course of major depression in patients with chronic hepatitis type c undergoing interferon-alpha therapy: A prospective study\u2019","volume":"25","author":"Horikawa","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v64n0614","article-title":"\u2018Psychiatric symptoms in patients with chronic hepatitis c receiving interferon alfa-2b therapy\u2019","volume":"64","author":"Kraus","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.44.2.104","article-title":"\u2018A prospective study of neuropsychiatric symptoms associated with interferon-\u03b1-2b and ribavirin therapy for patients with chronic hepatitis c\u2019","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2004.01.003","article-title":"\u2018Suicidal ideation during interferon-\u03b12b and ribavirin treatment of patients with chronic hepatitis c\u2019","volume":"26","author":"Dieperink","year":"2004","journal-title":"Gen Hosp Psychiatry"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.07035.x","article-title":"\u2018Effect of pegylated interferon-\u03b1-2a treatment on mental health during recent hepatitis c virus infection\u2019","volume":"27","author":"Alavi","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.45.5.947","article-title":"Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia","volume":"45","author":"Pavol","year":"1995","journal-title":"Neurology."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19980801)83:3<482::aid-cncr17>3.0.co;2-s","article-title":"\u2018Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial\u2019","volume":"83","author":"Caraceni","year":"1998","journal-title":"Cancer"},{"key":"B104","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(20000715)89:2<356::AID-CNCR21>3.0.CO;2-Z","article-title":"\u2018Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes\u2019","volume":"89","author":"Greenberg","year":"2000","journal-title":"Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.601939","article-title":"\u2018The hypothalamic-Pituitary-Adrenal axis: Development, programming actions of hormones, and maternal-fetal interactions\u2019","volume":"14","author":"Sheng","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2010.12.001","article-title":"\u201811\u03b2-hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress\u2019","volume":"32","author":"Wyrwoll","year":"2011","journal-title":"Front Neuroendocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11101298","article-title":"\u2018HPA axis in the pathomechanism of depression and schizophrenia: New therapeutic strategies based on its participation\u2019","volume":"11","author":"Mikulska","year":"2021","journal-title":"Brain Sci"},{"key":"B108","volume-title":"Physiology, cortisol","author":"Thau","year":"2022"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-378630-2.00040-2","article-title":"\u2018Gluconeogenesis\u2019","volume-title":"Encyclopedia of biological chemistry (Second edition)","author":"Hanson","year":"2013"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2011.02.016","article-title":"\u2018Chronic stress, cognitive functioning and mental health\u2019","volume":"96","author":"Marin","year":"2011","journal-title":"Neurobiol Learn Memory"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neuroscience.2011.12.030","article-title":"\u2018Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis\u2019","volume":"204","author":"Hill","year":"2012","journal-title":"Neuroscience"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102224","article-title":"\u2018Stress and the HPA axis: Balancing homeostasis and fertility\u2019","volume":"18","author":"Joseph","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-4328(02)00222-x","article-title":"\u2018The effects of chronic mild stress on male sprague-dawley and long Evans rats: I. biochemical and physiological analyses\u2019","volume":"136","author":"Bielajew","year":"2002","journal-title":"Behav Brain Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3934\/Neuroscience.2020028","article-title":"\u2018Stress and serum cortisol levels in major depressive disorder: a cross-sectional study\u2019","volume":"7","author":"Bertollo","year":"2020","journal-title":"AIMS Neurosci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(98)00882-8","article-title":"\u2018Morphological changes in the hippocampal CA3 region induced by non-invasive glucocorticoid administration: a paradox\u2019","volume":"809","author":"Magari\u00f1os","year":"1998","journal-title":"Brain Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.03.005","article-title":"\u2018Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: relevance to depression\u2019","volume":"34","author":"Sterner","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343833","article-title":"\u2018Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia\u2019","volume":"24","author":"Murialdo","year":"2001","journal-title":"J Endocrinological Invest"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00363","article-title":"\u2018Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain\u2019","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075058","article-title":"\u2018Abnormal functional connectivity of amygdala in late-onset depression was associated with cognitive deficits\u2019","volume":"8","author":"Yue","year":"2013","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1048592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T05:28:31Z","timestamp":1677043711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1048592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2023.1048592"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1048592","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"1048592"}}